Theravance Biopharma, Inc. Annual Income Tax Expense (Benefit) in USD from 2012 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Theravance Biopharma, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2012 to 2023.
  • Theravance Biopharma, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $2.65M, a 93.6% increase year-over-year.
  • Theravance Biopharma, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $8.71M.
  • Theravance Biopharma, Inc. annual Income Tax Expense (Benefit) for 2023 was $5.92M, a 65722% increase from 2022.
  • Theravance Biopharma, Inc. annual Income Tax Expense (Benefit) for 2022 was $9K.
  • Theravance Biopharma, Inc. annual Income Tax Expense (Benefit) for 2021 was -$151K, a 98.2% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $5.92M +$5.92M +65722% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-01
2022 $9K +$160K Jan 1, 2022 Dec 31, 2022 10-K 2024-03-01
2021 -$151K +$8.37M +98.2% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-01
2020 -$8.52M -$3.3M -63.2% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-01
2019 -$5.22M +$5.34M +50.6% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 -$10.6M -$24.3M -177% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 $13.7M +$3.58M +35.5% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-27
2016 $10.1M +$9.16M +963% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 $951K -$5.41M -85.1% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-28
2014 $6.36M +$6.36M Jan 1, 2014 Dec 31, 2014 10-K 2017-03-01
2013 $0 $0 Jan 1, 2013 Dec 31, 2013 10-K 2016-03-11
2012 $0 Jan 1, 2012 Dec 31, 2012 10-K 2015-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.